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SUMMARY 
The completion of the Plasmodium falciparum genome sequence has recently promoted 
the search for new antimalarial drugs. More specifically, metabolic pathways of the apicoplast, a 
key organelle for survival of the parasite, have been recognized as potential targets for the 
development of specific new antimalarial agents. As most apicomplexan parasites, P. falciparum 
displays a plant-type ferredoxin-NADP+ reductase, yielding reduced ferredoxin for essential 
biosynthetic pathways in the apicoplast. Here we report a molecular, kinetic and ligand binding 
characterization of the recombinant ferredoxin-NADP+ reductase from P. falciparum, at the light 
of current data available for plant ferredoxin-NADP+ reductases. In parallel with the functional 
characterization, we describe the crystal structures of P. falciparum ferredoxin-NADP+ reductase 
in free form and in complex with 2’-phospho-AMP (at 2.4 and 2.7 Å resolution, respectively). 
The enzyme displays structural properties likely to be unique of plasmodial reductases. In 
particular, the two crystal structures highlight a covalent dimer, which relies on the oxidation of 
residue Cys99 in two opposing subunits, and a helix-coil transition occurs in the NADP-binding 
domain triggered by 2’-phospho-AMP binding. Studies in solution show that NADP+, as well as 
2’-phospho-AMP, promotes the formation of the disulfide-stabilized dimer. The isolated dimer is 
essentially inactive, but full activity is recovered upon disulfide reduction. The occurrence of 
residues unique to the plasmodial enzyme, and the discovery of specific conformational 
properties, highlights the NADP-binding domain of P. falciparum ferredoxin-NADP+ reductase 
as particularly suited for the rational development of antimalarial compounds. 
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INTRODUCTION 
The protozoan parasite Plasmodium falciparum, responsible for the most deadly form of 
malaria, causes more than 1 million deaths each year.1 In this severe context, many drugs 
currently used to fight the infective disease are becoming less effective due to growing resistance 
displayed by the parasite in several countries, particularly in Southeast Asia. The completion of 
the P. falciparum genome sequence,2 as well as those of other apicomplexan parasites, has 
promoted many efforts in the search for new drug targets and for novel antimalarial agents. 
Prerequisites for an ideal drug target are that the selected protein be part of a unique metabolic 
pathway and essential for the survival or virulence of the parasite, but ideally not present in the 
human host. From this point of view, apicomplexan parasites may be remarkably vulnerable 
since they harbor a unique organelle, the apicoplast, which is a cryptic plastid originated from 
the secondary endosymbiosis of a red alga.3 This organelle has been shown to be essential for 
parasite survival both in P. falciparum and Toxoplasma gondii.4,5 Thus, the metabolic pathways 
present or supposed to be localized in the apicoplast6 are currently exploited as drug targets 
sources for the development of antimalarial agents.7
We have recently proposed the apicoplast redox system comprising the plant-type 
ferredoxin-NADP+ reductase (FNR) and its substrate, the iron-sulfur protein ferredoxin (Fd), as a 
new potential target for design of drugs against Apicomplexa.8 We previously reported the 
cloning, recombinant expression and biochemical characterization of this redox system from the 
apicomplexan T. gondii.9-12 More recently, it was shown that the FNR/Fd pair can reconstitute in 
vitro the electron transfer pathway from NADPH to the enzyme (E)-4-hydroxy-3-methyl-but-2-
enyl-diphosphate (HMBPP) reductase, also called LytB or IspH, that catalyzes the last step of the 
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mevalonate-independent isoprenoid biosynthesis in the apicoplast of the parasite.13 Several other 
apicoplast enzymes or pathways have been suggested to be dependent on the FNR/Fd redox 
system, among others the iron-sulfur cluster biogenesis in the apicoplast.8
All apicomplexan FNRs belong to the plant-type FNR family of enzymes, for which a 
very detailed functional and structural characterization has been provided over the last thirty 
years, as summarized in recent reviews.14-17 Up to now, the three-dimensional structure of 39 
wild-type and site-directed mutant FNR forms from 6 different eukaryotic and prokaryotic 
sources have been deposited in the Protein Data Bank, some of which are FNR complexes with 
either of the two substrates, Fd or NADP(H). 
In our continuous effort to understand the functional and structural aspects of plant FNRs 
but also to lay the foundations for exploiting apicomplexan FNRs as drug targets, we report here 
the basic biochemical characterization and three-dimensional structure of P. falciparum FNR 
(PfFNR) in two different crystal forms, in the absence and presence of the nucleotide analogue 
adenosine 2’,5’-diphosphate (2’P-AMP). We show that PfFNR undergoes a dimerization process 
that is dependent on the redox conditions and on the presence of NADP+ or 2’P-AMP, leading to 
a virtually inactive homodimeric enzyme. The structural data also show that conformational 
disorder affects protein loops that are specific of the apicomplexan parasite reductase, while 
conformational transitions at the 2’P-AMP site may promote formation of the dimeric species. 
Altogether, the data presented here shed first light on the functional and structural properties of a 
protozoan FNR, providing a rational basis for the design of inhibitors that might be developed 
into antimalarial drugs. 
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RESULTS 
a) Molecular and kinetic characterization of PfFNR − The absorbance spectrum of the purified 
recombinant PfFNR in the visible region is that typical of this flavoprotein family, with peaks at 
394 and 454 nm, and a A280/A454 ratio of 7.0. The presence of a modified flavin, as reported for 
the recombinant form of T. gondii apicomplexan FNR that contains variable amounts of 6OH-
FAD,18 could thus be excluded. An extinction coefficient of 10 mM-1 cm-1 (at 454 nm) was 
determined and used throughout for enzyme quantification. Being devoid of Trp residues, PfFNR 
displays very low protein fluorescence, and the FAD fluorescence is nearly fully quenched.  
PfFNR was homogeneous by SDS-PAGE analysis, and had an electrophoretic mobility 
consistent with the calculated theoretical mass of 37,267 Da. PfFNR was shown to be a 
monomer of 28 ± 1.4 kDa by gel filtration on a Superdex 75 column in FPLC. Following the 
crystallization results (see below) that indicated the presence of a disulfide-stabilized PfFNR 
dimer in both crystal forms analyzed, the six Cys residues of the enzyme were titrated with 
DTNB, both under native and denaturing conditions. These experiments revealed that only one 
Cys could be titrated in the native protein, and practically all Cys residues (5.45) were modified 
in the denatured enzyme. To further proof that the PfFNR intermolecular disulfide was the result 
of Cys oxidation occurring during crystal growth (i.e., on a long exposure to air) two protein 
samples were incubated at 20 °C in the presence and absence of 1 mM DTT, respectively. 
Aliquots were withdrawn at different times and gel-filtered on the Superdex 75 column, as 
described above (see Fig. 1A). After about seven days of aerobic incubation, a peak eluting in 
front of that corresponding to the PfFNR monomer was observed in the DTT-free sample. The 
molecular mass of this species was 44 ± 2 kDa, compatible with that expected for a PfFNR 
 6
dimer. The dimer peak grew in intensity with time, and was also observed in the aged sample 
containing 1 mM DTT. After addition of fresh DTT to both aged samples, gel-filtration showed 
only one protein peak corresponding to the monomeric species (data not shown).  
Taken together, these data indicate that formation of a disulfide-stabilized PfFNR dimer 
is related to spontaneous air oxidation occurring during the relatively long time needed for the 
growth of PfFNR crystals. The above experiments were repeated including 1 mM 2P’-AMP in 
the aerobic incubation mixtures. As shown in Fig. 1B, just after 1 h of incubation under these 
conditions, the dimer was detectable, its amount increasing rapidly to 37% after 1 day, and to 
73% after 4 days. Activity measurements after 4 days of incubation indicated that the mixture 
containing more than 70% of dimer was much less active (ca. 20%) than a control sample 
incubated for the same time. To evaluate whether formation of the dimer has any significance in 
vivo, NADP+ was used instead of 2P’-AMP in the incubation mixture. Indeed, as shown in 
Figure 1C, NADP+ as well is able to promote dimer formation with concomitant decrease of 
activity. Furthermore, dimer formation was studied with enzyme and coenzyme at more 
physiological concentrations by measuring residual activity. 4 μM PfFNR incubated with 200 
μM NADP+ yielded nearly the same amount of dimer, i.e., 10% at 1 h and 50% at 24 h versus 
12% and 49%, respectively (at 300 μM PfFNR, 1 mM NADP+, Fig. 1C). In all the above 
experiments, addition of 1 mM DTT completely dissociated the dimer and fully restored PfFNR 
enzymatic activity.  
The NADPH–K3Fe(CN)6 diaphorase reaction is typically used to kinetically characterize 
FNR enzymes, because of the simplicity of the assay and due to the fact that the reaction rate 
was shown to be limited by FAD reduction in the case of FNR from spinach leaves (SoFNR).19 
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At 1 mM ferricyanide and varying the NADPH concentration, an apparent kcat value of 214 s-1 
was determined for PfFNR, with a Km for NADPH of 172 μM. These values deviate 
significantly from those found for plant and T. gondii FNRs,10,19,20 the PfFNR activity being 
lower and Km for NADPH remarkably higher. By varying the concentration of the diaphorase 
reaction acceptor, a pattern became evident (i.e., rates increased upon decreasing the ferricyanide 
concentration) that could be fitted by an equation that considers ferricyanide acting as a 
competitive inhibitor of NADPH (Ki of 230 μM). This analysis yielded nearly the same kcat value 
reported above, while the apparent Km for NADPH was found substantially lower (Table 2). 
NADH was also tested as a possible electron donor in the ferricyanide reduction, but it turned 
out to be a poor substrate. The ratio of the specificity constants (kcat/KmNADPH divided by 
kcat/KmNADH) yielded a value of 70 indicating a much lower capacity of PfFNR to discriminate 
between the two pyridine nucleotides relative to the plant enzymes (specificity constant ratios ≥ 
30,000).  
The kinetic parameters were also determined for the PfFNR homodimeric species. The 
PfFNR dimer produced after 36 h of aerobic incubation in the presence of 1 mM NADP+ was 
isolated by gel-filtration as described above. The dimer exhibited the same spectral ratio 
A280/A454 as the monomeric species. The kcat value turned out to be only 5% of that of 
monomeric PfFNR, while the Km for NADPH was of the same order (ca. 23 μM; see Table 2). 
An alternative electron acceptor for FNRs is INT. As shown in Table 2, the values of the kinetic 
parameters for this reaction fall in the range observed for the other FNRs, except for the very 
high value of Km for NADPH. Using the INT assay, a Ki of 134 ± 14 μM (versus an apparent Km 
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for NADPH of 232 ± 15 μM) for 2’P-AMP, a typical competitive inhibitor of NADPH-
dependent enzymes, was measured. 
 
b) K3Fe(CN)6, 2’P-AMP and NADP+ binding − The difference spectrum in the visible region 
resulting from NADP+ binding to PfFNR showed, besides the positive peak at 508 nm, a second 
lower positive maximum at 475 nm, which in SoFNR-NADP+ complex difference spectrum is a 
small shoulder20,21 (Fig. 2A). Titrations of the enzyme at pH 7 with increasing concentrations of 
NADP+ allowed us to determine a Kd value of 35 ± 7 μM (vs 14 μM for SoFNR),21 which 
indicates a low affinity of PfFNR for the oxidized pyridine nucleotide. Titration of PfFNR with 
2’P-AMP yielded a canonical difference spectrum for the FNR enzymes21 (Fig. 2A), and a Kd 
value of 2.4 ± 1 μM (the same value of SoFNR).21 Since K3Fe(CN)6 was found to inhibit PfFNR, 
its interaction with the enzyme was also studied by difference spectroscopy. Addition of the dye 
to the oxidized enzyme also elicited spectral perturbations of PfFNR, resulting in a difference 
spectrum similar to that of the 2’P-AMP complex but with distinct features (Fig. 2A). The 
approximate value determined for Kd was in the same range as that found for Ki. To evaluate if 
competition for the same site (or overlap of the binding sites) between ferricyanide and 2’P-AMP 
takes place, titrations of the 2’P-AMP–enzyme complex with ferricyanide and viceversa were 
performed. Clearly, the two difference spectra were additive, excluding the binding of 
ferricyanide at the same site of 2’P-AMP. Similar experiments were performed with ferricyanide 
and NADP+. Titration of the NADP+-enzyme complex with K3Fe(CN)6 perturbed its difference 
spectrum producing a progressive decrease of the peak at 510 nm (which is typical for the 
NADP+-enzyme complex) with the concomitant appearance of the difference spectrum  of the 
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ferricyanide-enzyme complex (Fig. 2B). This suggests that ferricyanide competes with the NMN 
part of NADP+ for binding to the PfFNR active site.  
 
c) Overall structural properties of PfFNR − The two crystal forms of PfFNR reported here were 
obtained in the absence of 2’P-AMP (P3221 space group crystals) and in its presence (P31 space 
group crystals), respectively. As expected for this enzyme family,14 PfFNR consists of two 
domains: the N-terminal FAD binding domain, comprising residues 1 - 160, and the C-terminal 
NADP+ binding domain, built by residues 166 - 316 (Fig. 3A, B). Accordingly, the FAD domain 
hosts a β-barrel built by two perpendicular three-stranded antiparallel beta sheets (β1β2β5 and 
β3β4β6) and a single α-helix (αA), nestled between β5 and β6. The C-terminal domain hosts a 
five-stranded parallel β-sheet (β9β8β7β10β11), surrounded by seven α-helices (αB-αH). In both 
crystal forms PfFNR displays five disordered surface regions: the N-terminal residues 1-4, the 
long loop between β3 and β4 (residues 63-97), the β5-αA loop (residues 126-133), the αB-β9 
loop (residues 196-205), and the αH-αI (residue 299-305). Excluding such regions, the r.m.s. 
deviations calculated on 244 Cα atoms for the six independent protein chains (of the PfFNR/2’P-
AMP inhibitor complex, PfFNR/2’P-AMP) range between 0.30 and 0.58 Å, the main structural 
differences being located at the borders with the disordered regions. Structural comparisons with 
maize root FNR (ZmFNR, pdb id. 1JB9; 29% sequence identity) and SoFNR (pdb id. 1FND; 
25% sequence identity) yield r.m.s. deviations of 1.61 Å (234 Cα pairs) and 1.70 Å (237 Cα 
pairs), respectively. Slightly lower  r.m.s. deviation values (about 1.5 Å) result from structural 
overlays of PfFNR in the absence of 2’P-AMP (P3221 crystal form) with the same two plant 
enzymes.  
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 d) The FAD binding site − The FAD molecule is observed essentially in the same extended 
conformation in both crystal forms. The 7,8-dimethyl-isoalloxazine ring is hosted in a pocket 
between the two protein domains, sandwiched between the conserved C-terminal Tyr316 and 
four conserved amino acids of the β4 strand. The FAD adenine end points toward the protein 
surface, where slight orientation differences (about 1.5 Å) are observed in the two crystal forms 
(Fig. 3A, B). Schematically, the FAD molecule interacts with four main regions of PfFNR, 
largely through hydrogen bonds to/from atoms of the main chain. These regions comprise the 
strands β4 (Arg101 NH2, Leu102 O, Ser104 N atoms) and β5 (Ala117 O, Lys119 N, Tyr123 O 
atoms), the αA helix (Tyr137 N, Cys138 N, Ser139 Oγ atoms), and the conserved C-terminal 
Tyr316 at the end of strand β11. Two water molecules (w1 and w2) mediate interactions between 
the protein and the dimethyl-isoalloxazine ring through hydrogen bonds to its carbonyl oxygen 
atoms (O2 and O4): w1 bridges between His121 Nε2, Lys119 O, the ribitol hydroxyl O3 and O2, 
whereas w2 bridges between Ser104 O, Ala 117 atoms O and N, and the isoalloxazine carbonyl 
oxygen O4. The ribitol hydroxyl O3 is also hydrogen bonded to Tyr103 OH, whereas the FAD 
diphosphate moiety interacts with the N atom of Cys138, and with the N and O γ atoms of 
Ser139, the negative charges being partly compensated by Arg101. Finally, the adenine ring 
stacks over the phenolic ring of Tyr123. 
The overall FAD binding mode described for PfFNR is essentially conserved in ZmFNR 
and SoFNR, the main conformational differences affecting only the protein surface location of 
the cofactor’s adenosine moiety (displaced by 1.7 Å in ZmFNR and by 5 Å in SoFNR). Such 
surface location accounts for the (contained) mobility of the FAD adenosine end observed in two 
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crystal forms of PfFNR and in ZmFNR. Due to a varied disposition of the β5-αA loop, the FAD 
adenosine end is further projected towards the solvent in SoFNR, where it is also differently 
oriented, being stabilized only by a stacking interaction with Tyr120. The enhanced mobility of 
the adenine ring is stressed by considering the ratio of B factors between adenine atoms and 
atoms of the isoalloxazine ring within the FAD cofactor of different enzymes. This ratio is about 
2.5 for ZmFNR and PfFNR, but it is 11.8 in SoFNR. Given the location of the FAD adenine ring 
far from the active site region, such structural variations should bear little relevance for PfFNR 
catalysis. 
 
e) PfFNR structure in the absence of 2’P-AMP − The P3221 PfFNR crystals accommodate four 
molecules in the asymmetric unit; the crystal lattice packing gives rise to an open tetramer with 
approximate 222 symmetry (Fig. 3C). Within such a tetramer, covalent dimers based on an 
intermolecular disulfide bridge involving Cys99 (in the FAD binding domain) from facing 
PfFNR subunits can be recognized in the crystal structure (Fig. 3D). Two distinct association 
interfaces can be recognized in such tetrameric assembly. The first intermolecular association 
interface in the region surrounding the Cys99 disulfide covers 720 Å2. Such a contact region 
occurs in a part of the FAD binding domain that is characterized by disordered loops. The 
covalent dimeric association locates two FAD groups about 18 Å apart (closest approach) in anti-
parallel fashion. The second association interface (supporting non-covalent protomer association 
in the tetramer, via a local 2-fold axis) covers 460 Å2, and is built by helices αF and αH of 
opposing protomers, related by a local 2-fold axis. The FAD groups related by this association 
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interface fall 37 Å apart. Cα backbone superposition of 258 model built residues in the four 
PfFNR chains yields r.m.s.d. values in the 0.51 - 0.57 Å range.  
 
f) PfFNR/2’P-AMP complex structure − PfFNR/2’P-AMP crystallizes in the trigonal P31 space 
group, with six asymmetric unit complex moieties that are assembled into three evident dimers. 
Comparison with the enzyme structure reported above shows that 241 Cα atoms of PfFNR/2’P-
AMP match the PfFNR protein backbone with a r.m.s.d. of 0.80 Å. Association of the dimeric 
assembly relies on a contact surface of about 1420 Å2 on each protomer, being stabilized by the 
intermolecular Cys99-Cys99’ disulfide bridge reported above for the inhibitor-free protein (Fig. 
3E). Nevertheless, the dimeric PfFNR assembly achieved in the 2’P-AMP complex is essentially 
unrelated to that observed in the absence of the inhibitor. The two PfFNR protomers in 
PfFNR/2’P-AMP contact each other mostly through the active site surface, in such a way that 
parts of the FAD binding domains of the two protomers (and of the NADP+ binding domains as 
well) face each other, in a quaternary assembly displaying approximate 2-fold symmetry (Fig. 
3E). The association gives rise to a sort of central tunnel (open diameter of 6-7 Å), orthogonal to 
the dimer's 2-fold axis, defined by the four domains in the two protomers. The tunnel walls are 
lined by two FAD and two 2’P-AMP molecules. Water molecules are found at several different 
locations, mediating interactions at the dimer association interface. In each dimer two FAD 
molecules assemble in antiparallel fashion around the local 2-fold axis; the 7- and 8-methyl 
groups of one isoalloxazine ring contact (3.5 – 3.9 Å) one face of the adenine ring of the 
opposing FAD moiety. Additionally, two water molecules bridge between the ribitol O4 atoms 
of the two facing FAD molecules. Direct hydrogen bonding interactions are observed in the 
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NADP+ binding domain between the 2’P-AMP molecules of opposing protomers (see Section g) 
below). Electrostatic compensation between residues and the inhibitor and direct hydrogen bonds 
between residues of the two facing protomers can be distinguished in this subset of the 
association interface.  
 
g) The 2’P-AMP binding site − The 2’P-AMP molecule is located in a cleft at the C-terminal end 
of the core β sheet, in the NADP+ binding domain, as expected. The inhibitor interacts mostly 
with two regions: β9-αF (hydrogen bonds to Ser247 Oγ, Tyr258 OH, Gln260 Oε1 atoms), and 
β10-αH (hydrogen bonds to His286 Nε2, Ser288 Oγ atoms) of the C-terminal domain, and with 
Lys119 Nζ of the N-terminal domain. The negative charge of the 5’ phosphate is balanced by 
Lys119, by a putative sodium ion, and by His286, whereas the negative charge of 2’ phosphate 
can be compensated only by Lys287 and/or Lys292, both contributed from the opposing subunit 
in the dimeric assembly (Fig. 4). Moreover, the inhibitor’s 2’ phosphate is hydrogen bonded to 
the conserved residues Ser247 and Tyr258, and to Ser288 (the latter from the facing PfFNR 
subunit). Such series of interactions suggests that the achievement of inter-molecular 
electrostatic balance at the 2’ phosphate might be one of the driving forces guiding PfFNR 
dimerization induced by 2’P-AMP or by NADP+. 
The 2’P-AMP adenine moiety is stabilized by three hydrogen bonds: two connecting to 
the 2’-AMP adenine ring of the facing subunit (atoms N6 and N7, in a reversed Hogsteen A-A 
base pairing), and the third to Ser288 Oγ. The adenine is sandwiched between Tyr258 and 
His286, and parallel to both side chain rings, in a position matching that of 2’P-AMP in its 
complex with SoFNR,22 where the 2’ phosphate charge, however, is compensated intra-
 14
molecularly by the highly conserved residues Arg235 (Tyr248 in PfFNR) and Lys244 (Ser256 in 
PfFNR). Indeed, despite the sequence differences and the conformational transitions occurring at 
residues 248-257 and 289-298 of PfFNR upon binding of 2’P-AMP (described in Section h) ), 
the inhibitor binding mode appears essentially the same in the two enzymes, with 3 Å deviations 
in the position of the 5’ phosphate end. Finally, it should be noted that the locations of the 
adenine stacking residues Tyr258 and His286 (a PfFNR specific residue) are dictated in 
PfFNR/2’P-AMP by their interactions with the inhibitor 2’ and 5’ phosphate groups, described 
above.  
 The observed PfFNR/2’P-AMP crystal structure allows to draw some hypotheses on 
the binding mode of NADP+ to PfFNR. We model built a NADP+ molecule in PfFNR by transfer 
of the nucleotide structure from the 3D structure of the homologous NADP+ bound Pisum 
sativum FNR (bearing the Tyr308Ser mutation; PDB entry 1QFY) after proper structure 
superposition  (r.m.s.d deviation between the two protein backbones of 1.69 Å, for 239 Cα 
pairs). Inspection of the built PfFNR/NADP+ model indicates that both the 2’ and 5’ phosphate 
groups may keep the same disposition in the two enzymes, the 5’ phosphate falling next to the 
conserved residue Lys119. The nicotinamide ring can be easily fitted next to the FAD 
isoalloxazine ring, replacing the stacking interaction of Tyr316, potentially being stabilized by a 
hydrogen bond to the conserved residue Glu314. The NADP+ adenosine end matches closely the 
2’P-AMP binding mode in this PfFNR region. However, as described above, electrostatic 
balance of the 2’-phosphate (occurring with the two conserved residues Arg235 and Lys244 in 
SoFNR) is missing in PfFNR (where these residues are Tyr248 and Ser256). Such deficiency of 
electrostatic compensation, as described above for 2’P-AMP, could promote dimerization of 
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PfFNR/NADP+ via the interaction of the 2’ phosphate with residue Lys287 from the facing 
subunit (Fig. 4).  
 
h) Conformational transitions related to 2’P-AMP binding − The most striking differences 
evident from the structural comparison of PfFNR/2’P-AMP and PfFNR are located in the 
NADP+ binding domain; they involve the β9-αF loop (residues 248-257) and the αH helix 
(residues 289-298). In fact, in the absence of the inhibitor a hydrogen bonded salt bridge formed 
by His286 and the 2’P-AMP 5’ phosphate is severed, and the nearby αH helix is shifted towards 
the FAD binding pocket by about 2 Å. Concomitantly, the β9-αF loop is shortened by 7 residues 
relative to PfFNR/2’P-AMP, and the αF helix is elongated by two additional turns at its N-
terminus (residues Ser252-Tyr258) (Fig. 3A). Such conformational transition linked to binding 
of 2’P-AMP and affecting the β9-αF and αH regions (but also the αH-β11 loop, which is 
disordered in the PfFNR/2’P-AMP structure) has not been observed before in any FNR, and is 
also reflected by a hydrogen bond stabilizing the β9-αF short loop in the inhibitor-free enzyme 
(Fig. 3A). If 2’P-AMP were to bind to the PfFNR observed structure, the inhibitor adenosine 2’ 
phosphate moiety would collide with the amino acid region comprised between Lys249 and 
Ser256, whereas the 5’ phosphate would be in close contact with Ser252, thus explaining the 
large conformational readjustments affecting the β9-αF loop described above for PfFNR/2’P-
AMP (Fig. 3A). 
 
 
DISCUSSION 
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Amino acid sequence comparisons of PfFNR relative to plant, algal and plasmodial FNRs 
show that out of the four conserved Cys residues in the FNR family (i.e. Cys114, Cys132, 
Cys137 and Cys272, SoFNR numbering), only Cys132 and Cys272 are present in PfFNR, which 
however displays a total of six cysteines.9,23 As most apicomplexan enzymes, PfFNR contains 
two major sequence insertions of 28 and 5 amino acids, respectively. The longer insertion falls 
just before the FAD binding motif and the shorter is a few amino acids after the NADP+ binding 
GTG sequence motif. The first inserted segment is reflected by a disordered loop in both PfFNR 
and PfFNR/2’P-AMP structures, covering residues 62-96, after which the polypeptide chain 
returns to a defined conformation, also in consideration of the neighbouring Cys99 disulfide 
bridge. The 5-residue insertion occurs in a wide surface loop, also displaying conformational 
flexibility that hampers the observation of residues Asp196-Ser205 in the αB-β9 loop. These 
structural results are in full agreement with the data obtained by limited proteolysis on TgFNR.12 
Indeed, most of the protease cleavage sites identified in TgFNR fall in these sequence insertion 
segments. 
Several sequence differences, relative to plant FNRs, are present in the FAD and in the 
NADP+ binding motifs, which are otherwise highly conserved within the FNR family (Fig. 5). 
Among these the lack of two basic residues (Arg235 and Lys244) which have been shown to 
stabilize the 2’P of NADP+ and of 2’P-AMP in SoFNR22,24,25 is remarkable. This could explain 
the observed lower affinity for NADPH and NADP+ shown by PfFNR in comparison to other 
FNRs. The specific electrostatic features of the NADP(H)-binding site could result in subtle 
differences in the geometry of bound NADPH, causing the lower kcat value of the plasmodial 
enzyme in the NADPH-ferricyanide reductase reaction.  
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 The structural results reported here highlight the unexpected role of Cys99, a residue 
conserved (although not fully) in plasmodial FNRs; conversely, this site is never occupied by 
Cys in plant FNRs. PfFNR Cys99 acts specifically in the formation of an intermolecular 
disulfide bridge resulting in the enzyme association into dimers. The high reactivity displayed by 
Cys99 may be related to its full solvent accessibility, but also to the nearby location of positively 
charged residues, such as Lys13, Arg98 and Arg101, that may increase the residue's reactivity by 
enhancing its nucleophilic character. The crystallographic results show that binding of 2’P-AMP 
to PfFNR promotes formation of a compact dimer, whose subunit association interface is 
properly shaped by the enzyme interaction with the inhibitor. Such interaction requires a 
substantial restructuring of 12 residues in the β9 – αF region (undergoing a helix-coil transition 
for residues Asn251 – Phe257), and a 2 Å shift for the αH helix. It is remarkable that, despite the 
unique sequence displayed by PfFNR, the elongated αF helical structure seen in this region of 
inhibitor-free PfFNR changes into one that is topologically much closer to ZmFNR and SoFNR, 
showing a shorter αF helix and a longer β9 – αF solvent exposed loop.  
The dimeric assembly observed in 2’P-AMP-free PfFNR might represent a resting state 
of PfFNR, once the Cys99 disulfide is formed. Inspection of the 3D structures indicates that the 
inhibitor-free PfFNR assembly cannot give rise to the quaternary structure of PfFNR/2’P-AMP 
for two main reasons. On one hand, the extended α-F helix alters the subunit association 
interface and would yield intermolecular collisions at the 2’P-AMP binding sites. On the other, 
the (electrostatic) intermolecular interactions established by the inhibitor and the opposing 
enzyme subunit are obviously missing. None of the structural data, however, helps in assessing 
whether the observed dimeric form has a functional role within the apicoplast, where specific 
 18
(yet uncharacterized) redox properties may prove crucial in promoting/preventing formation of 
the dimer-stabilizing disulfide bridge. 
Our results show that in dimeric PfFNR/2’P-AMP the inhibitor 2’ phosphate may be 
counterbalanced by the positive charges of Lys287 and/or Lys292 of the facing subunit, being 
stabilized by intra- and intermolecular hydrogen bonds. The crystal structure of PfFNR/2’P-AMP 
shows that His286, that appears to be unique to the PfFNR sequence, contributes substantially to 
stabilization of the 2’P-AMP inhibitor, since it is stacking over the adenine aromatic ring (the 
other stacking partner on the opposite adenine face being Tyr258) and it is hydrogen bonded to 
the inhibitor 5’ phosphate. At the crystallization pH of 6.0 the His286 – 2’ phosphate interaction 
is likely to display also a strong ion pair character. This residue is part of a loop (residues 284-
291) proposed to be involved in NAD(P)(H) recognition and to represent one of the determinants 
of coenzyme specificity within the FNR superfamily.26 Indeed, it has been shown by site-
directed mutagenesis that Leu263 of Anabaena FNR, equivalent to His286 of PfFNR, plays a 
significant role in NADPH binding and discrimination against NADH,27 though it provides only 
a modest apolar contact to the adenine ring of the ligand.22,28
 From the functional viewpoint the ability of PfFNR to undergo a redox-linked 
inactivation/reactivation process based on a disulfide/dithiol interchange at Cys99 is so far 
unique in the FNR family. As shown by the crystal structures and the gel filtration experiments, 
the observed active and inactive forms of PfFNR correspond to its monomeric and disulfide-
stabilized dimeric states, respectively. Thus, the results here reported allow us to rationalize on a 
molecular basis the very low catalytic activity of the disulfide-linked homodimeric form of the 
enzyme. Indeed, the 2’P-AMP-bound form of dimeric PfFNR adopts a very compact quaternary 
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structure, where both NADP- and Fd-binding sites are poorly accessible. It can be speculated that 
during the catalytic cycle the dimeric form of PfFNR stalls in a conformation similar to that 
observed for the PfFNR/2’P-AMP complex, where 2’P-AMP would be replaced by NADP+. 
Under these conditions, both NADP+ release and electron transfer from FADH2 to the acceptor 
substrate should be impaired, justifying the low kcat value displayed by the PfFNR dimer in the 
ferricyanide reductase activity. 
 The comparison of two crystal forms of PfFNR additionally suggests a mechanism 
explaining the onset of enzyme inactivation triggered by NADP+ or its analog. We hypothesize 
that the active, free-thiol form of PfFNR can exist in solution as an equilibrium mixture of 
monomer and non-covalent homodimer. When NADP+ (or its analog) is bound, the PfFNR 
dimer is expected to match closely the quaternary structure of the PfFNR/2’P-AMP complex 
observed in the crystals, which is stabilized by a relatively wide subunit interface involving the 
bound ligand. Conversely, in the absence of NADP+, the non-covalent (dimer forming) 
interactions are destabilized due to partial reorganization of the C-terminal domain and to the 
lack of the bridging contacts provided by the ligand. The presence of NADP+ would therefore 
drive the monomer-dimer equilibrium towards subunit association, while in the absence of 
NADP+, PfFNR dimers would hardly be present. The close proximity of two Cys99 β-SH groups 
from facing subunits in the PfFNR non-covalent dimer would promote thiol oxidation to 
disulfide, and covalent stabilization of the dimer. 
 The observed rate of Cys99 disulfide formation is relatively low when O2 is the oxidant 
species. The rates of dithiol/disulfide interconversion are expected to be substantially higher in 
vivo, where the process can be speeded up by appropriate catalysis. It is noteworthy in this 
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respect that when oxidants other than oxygen (e.g., diamide) are used, the disulfide-linked dimer 
is formed in vitro at much higher rates (data not shown). Redox regulation of enzymes through 
disulfide bond formation is a common theme in plant metabolism. In addition to the well known 
examples described in chloroplasts, similar regulatory mechanisms have been recently observed 
in plant non-photosynthetic plastids where thioredoxins are held to play a central role in redox 
regulation.29 Although a number of genes encoding either thioredoxin (Trx), putative Trxs or 
Trx-related proteins, and one encoding a Trx-reductase (TrxR), are present in P. falciparum 
genome, none has been described so far to be targeted to the apicoplast.30 In a recent publication, 
Nickel et al.31 suggested that two P. falciparum proteins (Trx2 and Trx3) are presumably 
apicoplast-resident thioredoxins, based on the detection of a predicted signal peptide at the N-
terminus. However, in vivo targeting experiments are needed since such conclusion is not 
supported by other prediction algorithms (see 
http://v4-4.plasmodb.org/restricted/PlasmoAPcgi.shtml). 
Apicoplast-resident thioredoxins would also require a thioredoxin reductase, but the 
single essential TrxR in P. falciparum is cytosolic. Therefore, alternative redox regulators should 
be sought to prevent PfFNR dimerization in vivo. One attractive possibility would be the 
involvement of lipoic acid (LA). Lipoate and dihydrolipoate constitute a strong redox couple (Eo 
= -290 mV), and LA is synthesized in the apicoplast.32,33 Here, they exist as the protein-bound 
form in the E2 subunit of the apicoplast-resident pyruvate dehydrogenase complex34, and 
probably to some extent also as lipoyl-containing small peptides or lipoyl-lysine, due to normal 
protein-turnover. Free, unbound LA is presumably not present in the apicoplast35 however, it has 
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been shown that protein-bound LA may interact with external disulfides in its vicinity, including 
thioredoxins.36
 
CONCLUSIONS 
 The first crystal structures of an apicomplexan FNR reveal structural properties that are 
unique to plasmodial FNRs. Besides the extensive loop flexibility observed in two independent 
crystal structures and the new dimerization mechanism based on the oxidation of residue Cys99 
in two opposing PfFNR subunits, a helix-coil transition has been shown to occur in the substrate 
(i.e., NADP+) binding region, where the 2’P-AMP inhibitor is bound. The occurrence of specific 
residues, unique of the plasmodial enzyme, that support such a conformational transition, renders 
this region of the PfFNR protein structure very attractive for the development of antimalarial 
compounds. 
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MATERIALS AND METHODS 
NADH, NADP+, NADPH, 2’P-AMP and K3Fe(CN)6 were purchased from Sigma; all 
other chemicals were of the highest grade, and used without further purification. Recombinant 
PfFNR was expressed and purified as described previously.13
 
Spectral Analyses − Absorption spectra were recorded either on an Agilent 8453 diode-array, or 
a Cary 100 double-beam (Varian) spectrophotometer. The PfFNR extinction coefficient (for the 
protein-bound flavin) was determined spectrophotometrically.37 Steady-state kinetic parameters 
were determined for the NAD(P)H-K3Fe(CN)6 reductase, and the NADPH-INT reductase 
activities, as previously described.10,20 The concentrations of both, the electron donor and the 
electron acceptor, were independently varied. Initial rate data were fitted to the equation for a 
ping-pong Bi-Bi mechanism by non-linear regression using the GraFit 5.0 software package 
(Erithacus Software Ltd., United Kingdom).  
 
Molecular characterization methods − SDS-PAGE was carried out on 12% polyacrylamide gels. 
Analytical gel-filtration analyses were performed on an ÄKTA FPLC apparatus equipped with a 
Superdex 75 HR 10/30 column, equilibrated in 20 mM Tris-HCl, pH 7.4, containing 100 mM 
NaCl. 
 
Active-Site Titrations − Titrations of PfFNR (15 µM) with either NADP+, 2’P-AMP, and 
K3Fe(CN)6 were performed spectrophotometrically in 20 mM Tris-HCl, pH 7.6, at 16 °C using a 
Cary 100 (Varian) double-beam spectrophotometer. During titrations, spectra were recorded 
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initially and after additions of equal aliquots of ligand to the sample and reference cells. 
Difference spectra were computed by subtracting from each spectrum that obtained in the 
absence of ligand, after correction for dilution. Kd values were obtained by fitting data sets by 
nonlinear regression to the theoretical equation for a 1:1 binding.38 Cys residues of PfFNR were 
titrated with DTNB (5,5’-dithiobis (2-nitrobenzoic acid)) under native conditions and after 
denaturation with 6 M guanidinium chloride, in 100 mM Na-phosphate, pH 7, containing 10% 
glycerol and 1 mM EDTA.39
 
Crystal growth and structure solution − PfFNR was co-crystallized with 2’P-AMP in batch setup 
under a 1:1 mix of paraffin and silicon oil, using an Oryx-6 crystallization robot (Douglas 
Instruments Ltd, UK). In particular, a 0.46 μl droplet containing the protein solution (28 mg/ml 
PfFNR, 10% glycerol, 50 mM Tris-HCl, pH 7.4, 1 mM DTT, 1 mM 2’P-AMP) was added to a 
0.23 μl droplet containing the precipitant solution (22-25% PEG 4000, 0.1 M sodium cacodylate, 
pH 6.0, 0.2 M sodium acetate). The crystals grew in 2-3 weeks, at 294 K, as 150x150x50 μm3. 
X-ray diffraction data were collected at 100 K (ESRF, Grenoble, beam line ID14-3) after 30 s of 
crystal soaking in a cryoprotectant solution (27% PEG 4000, 0.2 M sodium acetate, 0.1 M 
sodium cacodylate, pH 6, 26% glycerol). The data were indexed using the program Mosflm,40 
showing that the crystals belong to a primitive hexagonal space group, with unit cell parameters 
a = b = 123.1 Å, c = 133.8 Å. Scaling and merging of the data (to 2.7 Å resolution) using the 
program Scala41 suggested two equally likely space groups: P3 (Rmerge = 16.0%), or P321 (Rmerge 
= 16.6%). The latter was chosen for the subsequent stages, based on the higher symmetry.  
 24
Molecular replacement searches, based on the Program Molrep42 using as search model 
the structure of maize root FNR (pdb 16B9), allowed us to locate three FNR chains in the 
crystallographic asymmetric unit and assign the space group as  P3121 (VM = 2.6 Å3/Da, solvent 
content 52.5%). The corresponding R-factor and correlation coefficient values for the molecular 
replacement solution were 56.1% and 40.0%, respectively, for the data at 2.7 Å resolution, after 
rigid body refinement of the three independent protein chains. The protein model was 
subsequently refined using the program Refmac,43 with a drop of the Rgen/Rfree values to 28.1% / 
33.9%, after several refinement cycles. At this stage clear electron density for an additional FNR 
molecule became evident in the crystallographic asymmetric unit. Such an observation, together 
with the occurrence of crystal packing intermolecular clashes, suggested to reduce the space 
group symmetry to P31. After rescaling of the data (resolution 2.7 Å, Rmerge = 10.2%), the well 
packed PfFNR dimer observed in the above refinement stages was used as search model, using 
Phaser,44 now locating three PfFNR dimers in the crystallographic asymmetric unit. This model 
(6 independent PfFNR chains) was then refined using Refmac and modeled with O45 (data at 2.7 
Å resolution; Rgen/Rfree= 24.3/31.7%). Each chain could be modeled in the 5–316 residue range, 
with the exclusion of the four regions 62-98, 126-133, 202-203 and 299-304, which displayed 
weak/absent electron density. Moreover, each subunit contained one FAD and one 2’P-AMP 
molecule (see Table 1). Additional crystallization experiments (using the same experimental 
setup) also yielded usable crystals at lower protein and inhibitor concentrations. In this case a 
0.33 μl protein solution droplet (25 mg/ml PfFNR, 10% glycerol, 50 mM Tris-HCl, pH 7.4, 1 
mM DTT, 0.5 mM 2’P-AMP, 0.2 mM Zinc acetate) was added to a 0.17 μl droplet containing 
the precipitant solution (22% PEG 4000, 0.1 M sodium citrate, pH 5.4, 0.2 M ammonium 
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acetate). Prismatic shaped crystals grew after 2-3 weeks at 291 K. Diffraction data were collected 
at ESRF beam line ID23-1, up to 2.4 Å resolution. Data reduction and scaling (programs 
Mosflm/Scala) showed that this crystal form belongs to the trigonal space group P3221 (or 
enantiomorph), with unit cell parameters a = b = 138.0 Å c = 147.4 Å, accommodating four 
molecules in the crystal asymmetric unit (Matthews coefficient 2.7 Å3/Da, solvent content 
54.8%). The structure was solved by molecular replacement (program Phaser)44 and refined 
using Refmac5 and manual rebuilding.43,45 The four refined molecules (Rgen/Rfree= 19.5/24.5%) 
display electron density for amino acids 5-316, with the exclusion of the regions 64-97, 126-133 
and 197-202. The final refinement parameters are listed in Table 1.  
 
Figures 
Figures 3 and 4 were produced using CCP4mp.46
 
Protein Data Bank Acsession codes 
Atomic coordinates and structure factors for both PfFNR and the PfFNR/2’P-AMP 
complex have been deposited with the Protein Data Bank, with entry codes  …, ..., respectively. 
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FIGURE CAPTIONS 
 
Fig. 1. Formation of the disulfide-linked homodimeric form of PfFNR in solution. 300 μM 
PfFNR was incubated in the absence or in the presence of ligands at 20 °C in 50 mM Tris-HCl, 
pH 7.4, containing 10% glycerol. 8 μl aliquots were assayed by gel filtration on a Superdex 75 
HR 10/30 column in 20 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, after different 
incubation times: thin solid line, 1 h; dotted line, 1 day; thick solid line, 4 days; dashed line, 7 
days. A, no ligand; B, 1 mM 2’P-AMP; C, 1 mM NADP+. 
 
Fig. 2. Binding of various ligands to PfFNR as studied by difference spectrophotometry. All 
enzyme titrations were carried out in 50 mM Tris-HCl, pH 7.6 at 16 °C. A, difference extinction 
coefficient of the binary complexes between PfFNR and 2’P-AMP (dashed line), NADP+ (thin 
solid line) or K3Fe(CN)6 (thick solid line). B, titration with K3Fe(CN)6 of 20.4 μM PfFNR in the 
presence of 116 μM NADP+. The reported spectra were recorded in the presence of the following 
concentration of ferricyanide: 0 (thin solid line), 50 μM (dotted line), and 470 μM (thick solid 
line). Intermediate titration spectra were omitted for clarity. 
 
Fig. 3. Tertiary/quaternary structures in PfFNR and its 2’P-AMP complex. (A) the structure of 
one isolated chain of PfFNR (inhibitor-free, yellow ribbon) is overlaid on the structure of 
PfFNR/2’P-AMP (blue ribbon).  The bound FAD (left) and 2’P-AMP (right) molecules are 
displayed as stick models. The lower right part of Panel A highlights the conformational helix-
coil transition occurring at the β9-αF loop, in the NADP+ domain, in the absence of the 
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nucleotide.  (B) (drawn in the same orientation of Panel A) shows the PfFNR/2’P-AMP 
polypeptide chain (monomer), color coded for the atomic B-factors; red shows the highest 
temperature factors (B=60 Å2), blue the lowest (B=10 Å2). The FAD domain is on the left and 
the NADP+ binding domain on the right. FAD and 2’P-AMP are displayed as cyan/red stick 
models. Note several interrupted segments on the protein surface, corresponding to regions of 
poor electron density.  (C) View of the quaternary assembly observed in the crystal asymmetric 
unit of PfFNR. The four protein chains are shown in yellow, violet, orange and green, 
respectively, displaying their respective FAD bound species as stick models.  (D) View of the 
dimeric assembly observed for the disulfide-stabilized PfFNR. The two protein chains are shown 
in yellow and green, respectively, displaying their respective FAD bound species as stick 
models. The yellow PfFNR subunit has the same orientation adopted in Panels A and B (two 
FAD groups are on the left hand side). The Cys99 disulfide, drawn in yellow, is labelled within a 
square window.  (E) Stereo view of the covalent PfFNR/2’P-AMP dimer. The two PfFNR 
molecules are shown in blue and orange, respectively. The Cys99 disulfide is highlighted by a 
square box, and labelled. Two FAD molecules are shown as yellow stick models; 2’P-AMP stick 
models are in cyan. The blue subunit has the same orientation of the protein chain in Panels A 
and B. 
 
Fig. 4. Electrostatics at the PfFNR NADP+ binding site. (A) shows a mono view of the enzyme 
surface, colour coded for the distribution of electrostatic charges, around the 2’P-AMP (the 
lower green stick model in the figure; the 2’ and 5’ phosphate groups are labelled), and the FAD 
binding sites (the overall orientation of the protein is close to that of Figs. 3 A,B). A lack of 
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positive charge around the 2’ phosphate group is evident, if just one PfFNR/2’P-AMP subunit is 
considered, as in this figure. 
(B) when the PfFNR/2’P-AMP dimer is assembled, the electrostatic contribution of residues 
provided by the opposing subunit becomes evident around the 2’ phosphate group of the 
inhibitor, as shown by the wider distribution of positive electrostatic charge (blue colour). Part of 
the secondary structure building the NADP+ binding domain is shown as cyan ribbons. (colour 
code: red =-10 kT/e, white=0 kT/e, blue=10kT/e). 
 
Fig. 5. Multiple sequence alignment of PfFNR, SoFNR, ZmFNR and TgFNR limited to the 
NADP+ and 2’P-AMP recognition residues. The secondary structure elements (H, for α-helix; E, 
for β-strand) detected in the two crystal structures here reported are displayed in the lower lines. 
The sequence numbering is referred to SoFNR (above) and PfFNR (below). The highlighted 
residues are those interacting with the 2’P of NADP. 
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Table 1. Data collection and refinement statistics for PfFNR and its complex with 2’P-AMP 
 
Data collection Statistics PfFNR PfFNR-2’P-AMP 
Resolution [Å] 92.90 -2.40 61.60 - 2.70 
Space group P3221 P31
Mosaicity [°] 0.4 0.7 
Rmerge [%] 8.1 (48.9)# 10.2 (47.6)*
Total Observations  207307 (30565) 165850 (24078) 
Unique Observations 63426 (9180) 61398 (8933) 
Mean(I)/sd(I) 10.3 (2.9) 9.8 (2.3) 
Completeness [%] 99.5 (99.7) 98.5 (98.1) 
Multiplicity  3.3 (3.3) 2.7 (2.7) 
   
Refinement Statistics   
R/Rfree [%] 19.5/24.5 24.3/31.7 
R.M.S. Bond lengths [Å] 0.010 0.008 
R.M.S. Bond angles [°] 1.30 1.27 
Ramachandran Plot:   
Resid. in most fav. reg. [%] 91.3 88.4 
Resid. in add. allow. reg. [%] 8.6 11.6 
*High resolution shell: 2.85-2.70 Å 
#High resolution shell: 2.53-2.40 Å 
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Table 2. Kinetic parameters of PfFNR 
 
REACTION 
kcat 
(e-eq s-1) 
KmNAD(P)
H (μM) 
kcat/KmNAD(P)H
 
(s-1μM-1) 
Kmacceptor 
(μM) 
kcat/Kmacceptor
(s-1μM-1) 
KiFeCN 
(μM) 
NADPH→K3Fe(CN)6a 250 ± 7.7 36 ± 5.7 7 ± 1 / / 230 ± 40 
NADH→K3Fe(CN)6a 96 ± 4 720 ± 90 0.1 ± 0.01 / / 185 ± 22 
NADPH→INTb 180 ± 11 350 ± 30 0.5 ± 0.05 95 ± 9 2 ± 0.2 / 
aActivity was assayed at 25 °C in 100 mM Tris-HCl, pH 8.2 
bActivity was assayed at 25 °C in 200 mM Tris-HCl, pH 9.0, containing 70 mM NaCl and 0.1% 
Triton-X100 
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                               235       245       255       265       275       285  
Spinach_leaf_FNR      NF-RLDFAVSREQTNEKGEKMYIQTRMAQYAVELWEMLKKDNTYFYMCGLKGMEKGIDDIMVS 
Maize_root_FNR        NF-RYDKALSREQKNRSGGKMYVQDKIEEYSDEIFKLLD-GGAHIYFCGLKGMMPGIQDTLKK 
T.gondii_FNR          NFVDIHFALSRQMKNPQGKKLYIQDVVWQEREKVWKALDRDGGHLYACGLKNMMVGVHEVLGN 
P.falciparum_FNR      NI-NIHYVFSYKQ-NSDATSFYVQDEIYKRKTEFLNLFNNYKCELYICGHKSIRYKVMDILKS 
                              248       257       267       277       287       297 
P3221                 EE-EEEEE          HHHHHHHHHHH HHHHHHHHH    EEEEEE  HHHHHHHHH  
P31                   EE-EEEEE              HHHHH   HHHHHHHHHH   EEEEEE GGGGGHHHHH    
                          β9                 αF          αG       β10       αH  
 
 
Fig. 5 
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